$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000142072023000045 Filed on September 27, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$50.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	-$2.750M	$2.610M	$18.45M
YoY Change	-154.05%	-70.5%	-43.0%
% of Gross Profit
Research & Development	$1.606M	$2.360M	$10.33M
YoY Change	-36.97%	-62.75%	-41.75%
% of Gross Profit
Depreciation & Amortization	$165.0K	$250.0K	$674.0K
YoY Change	-39.11%	-69.62%	-70.37%
% of Gross Profit
Operating Expenses	$5.153M	$4.970M	$29.34M
YoY Change	-32.52%	-67.26%	-43.42%
Operating Profit	-$5.103M		-$29.34M
YoY Change	-33.17%		-40.95%
Interest Expense	$26.00K	$30.00K	$83.00K
YoY Change	-73.74%	-118.99%	-94.12%
% of Operating Profit
Other Income/Expense, Net	$29.00K	$0.00	$32.00K
YoY Change	-70.71%		-105.21%
Pretax Income	-$5.070M	-$4.930M	-$29.31M
YoY Change	-32.73%	-71.09%	-41.73%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$5.746M	-$6.030M	-$65.01M
YoY Change	-68.31%	-64.64%	29.24%
Net Earnings / Revenue	-11492.0%
Basic Earnings Per Share	-$0.24		-$5.31
Diluted Earnings Per Share	-$0.24	-$7.01	-$5.31
COMMON SHARES
Basic Shares Outstanding	27.59M	16.80M	12.25M
Diluted Shares Outstanding	23.97M		12.25M

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.500M	$4.300M	$4.300M
YoY Change	-91.42%	-87.17%	-87.17%
Cash & Equivalents	$1.461M	$4.301M	$4.300M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$21.60M	$21.80M	$21.80M
YoY Change	-45.9%	1307.36%	1307.36%
Inventory	$0.00	$0.00
Prepaid Expenses
Receivables	$0.00	$0.00	$0.00
Other Receivables		$200.0K	$200.0K
Total Short-Term Assets	$23.02M	$26.26M	$26.30M
YoY Change	-63.78%	-41.74%	-41.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.054M	$4.219M	$7.600M
YoY Change	17.03%	-88.49%	-81.8%
Goodwill
YoY Change
Intangibles	$5.383M	$5.388M
YoY Change	-10.48%	11.07%
Long-Term Investments
YoY Change
Other Assets	$300.0K	$300.0K	$300.0K
YoY Change	-95.06%	-95.08%	-95.08%
Total Long-Term Assets	$14.66M	$14.95M	$14.90M
YoY Change	-30.21%	-72.49%	-72.58%
TOTAL ASSETS
Total Short-Term Assets	$23.02M	$26.26M	$26.30M
Total Long-Term Assets	$14.66M	$14.95M	$14.90M
Total Assets	$37.68M	$41.21M	$41.20M
YoY Change	-55.44%	-58.55%	-58.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.911M	$1.849M	$1.800M
YoY Change	-60.25%	-56.64%	-57.79%
Accrued Expenses	$3.391M	$4.034M	$4.400M
YoY Change	30.67%	7.17%	13.84%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$12.60M	$12.90M	$12.90M
YoY Change
Long-Term Debt Due	$400.0K	$400.0K	$400.0K
YoY Change	-98.22%	-98.2%	-98.2%
Total Short-Term Liabilities	$20.71M	$21.58M	$21.60M
YoY Change	-35.69%	-29.09%	-29.03%
LONG-TERM LIABILITIES
Long-Term Debt	$500.0K	$600.0K	$600.0K
YoY Change	-13.19%	1900.0%	1900.0%
Other Long-Term Liabilities	$3.300M	$3.700M	$3.700M
YoY Change	-3.54%	-32.17%	-32.17%
Total Long-Term Liabilities	$3.800M	$4.300M	$4.300M
YoY Change	-4.93%	-21.6%	-21.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.71M	$21.58M	$21.60M
Total Long-Term Liabilities	$3.800M	$4.300M	$4.300M
Total Liabilities	$24.47M	$25.83M	$25.80M
YoY Change	-32.4%	-28.1%	-28.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$294.7M	-$288.9M
YoY Change	21.74%	29.03%
Common Stock	$307.9M	$304.3M
YoY Change	5.93%	5.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.21M	$15.38M	$15.40M
YoY Change
Total Liabilities & Shareholders Equity	$37.68M	$41.21M	$41.20M
YoY Change	-55.44%	-58.55%	-58.55%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$5.746M	-$6.030M	-$65.01M
YoY Change	-68.31%	-64.64%	29.24%
Depreciation, Depletion And Amortization	$165.0K	$250.0K	$674.0K
YoY Change	-39.11%	-69.62%	-70.37%
Cash From Operating Activities	-$5.340M	-$4.970M	-$30.44M
YoY Change	-61.75%	-56.79%	-18.79%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$510.0K	$5.738M
YoY Change	-100.0%	-114.87%	-21.72%
Acquisitions			$692.0K
YoY Change
Other Investing Activities	$50.00K	$500.0K	$13.44M
YoY Change	-98.44%	-87.2%	106.67%
Cash From Investing Activities	$50.00K	-$10.00K	$7.009M
YoY Change	72.41%	-102.1%	-236.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.472M	2.740M	2.301M
YoY Change	116.65%	-27500.0%	-137.57%
NET CHANGE
Cash From Operating Activities	-5.340M	-4.970M	-30.44M
Cash From Investing Activities	50.00K	-10.00K	7.009M
Cash From Financing Activities	2.472M	2.740M	2.301M
Net Change In Cash	-2.818M	-2.240M	-21.09M
YoY Change	-77.97%	-79.7%	-56.72%
FREE CASH FLOW
Cash From Operating Activities	-$5.340M	-$4.970M	-$30.44M
Capital Expenditures	$0.00	$510.0K	$5.738M
Free Cash Flow	-$5.340M	-$5.480M	-$36.17M
YoY Change	-67.51%	-32.12%	-19.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12245000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8721000
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12245000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8721000
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.39
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.39
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.92
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.39
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.78
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	400000
CY2023Q1	ibio	Period For Payment From Issuance Of At Market Facility PeriodForPaymentFromIssuanceOfAtMarketFacility	P5D
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.04
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.39
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.39
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.92
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.39
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.78
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35023
CY2023	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2797813
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	8800 HSC Parkway
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bryan
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77807-1107
CY2023	dei	City Area Code CityAreaCode	302
CY2023	dei	Local Phone Number LocalPhoneNumber	355-0650
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	IBIO
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	5435812
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27586499
CY2023	dei	Auditor Firm AuditorFirmId	596
CY2023	dei	Auditor Name AuditorName	CohnReznick LLP
CY2023	dei	Auditor Location AuditorLocation	Holmdel, New Jersey
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4301000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22676000
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	3025000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000
CY2023Q2	ibio	Subscription Receivable Current SubscriptionReceivableCurrent	204000
CY2022Q2	us-gaap	Settlement Assets Current SettlementAssetsCurrent	5100000
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	664000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1549000
CY2023Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	18065000
CY2022Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	3900000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	26259000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	45070000
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	253000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5996000
CY2023Q2	ibio	Convertible Promissory Note Receivable And Accrued Interest ConvertiblePromissoryNoteReceivableAndAccruedInterest	1706000
CY2022Q2	ibio	Convertible Promissory Note Receivable And Accrued Interest ConvertiblePromissoryNoteReceivableAndAccruedInterest	1631000
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	610000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2722000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3068000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4219000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373000
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5388000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	50000
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	29000
CY2022Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	74000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	37314000
CY2023Q2	us-gaap	Assets Assets	41207000
CY2022Q2	us-gaap	Assets Assets	99406000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1849000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4264000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4034000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3764000
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	272000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	389000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	91000
CY2023Q2	ibio	Equipment Financing Payable Current EquipmentFinancingPayableCurrent	160000
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	12937000
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	22161000
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000
CY2023Q2	ibio	Current Liabilities Related To Assets Held For Sale CurrentLiabilitiesRelatedToAssetsHeldForSale	1941000
CY2022Q2	ibio	Current Liabilities Related To Assets Held For Sale CurrentLiabilitiesRelatedToAssetsHeldForSale	56000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21582000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	30436000
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	351000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3125000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3514000
CY2023Q2	ibio	Equipment Financing Payable Noncurrent EquipmentFinancingPayableNoncurrent	241000
CY2023Q2	ibio	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	527000
CY2022Q2	ibio	Noncurrent Liabilities Related To Assets Held For Sale NoncurrentLiabilitiesRelatedToAssetsHeldForSale	1971000
CY2023Q2	us-gaap	Liabilities Liabilities	25826000
CY2022Q2	us-gaap	Liabilities Liabilities	35921000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20310077
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20310077
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8727158
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8727158
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	20000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	9000
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	304301000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	287619000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-213000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288940000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223930000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	15381000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	63485000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41207000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99406000
CY2022	us-gaap	Revenues Revenues	1884000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10327000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9827000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19016000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21754000
CY2023	us-gaap	Operating Expenses OperatingExpenses	29343000
CY2022	us-gaap	Operating Expenses OperatingExpenses	31581000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-29343000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-29697000
CY2023	us-gaap	Interest Expense InterestExpense	83000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	213000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	177000
CY2023	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-98000
CY2022	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	7000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	184000
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-29311000
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-29513000
CY2022	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-1000
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-29311000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-29512000
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000
CY2023	ibio	Net Loss Available To Stockholders From Continuing Operations NetLossAvailableToStockholdersFromContinuingOperations	-29311000
CY2022	ibio	Net Loss Available To Stockholders From Continuing Operations NetLossAvailableToStockholdersFromContinuingOperations	-29600000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-35699000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-20791000
CY2023	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-65010000
CY2022	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-50391000
CY2023	us-gaap	Profit Loss ProfitLoss	-65010000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	180000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-150000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	33000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-64797000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-50454000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.39
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.39
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.92
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.39
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.31
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.78
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12245000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8721000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	108568000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	967000
CY2022	ibio	Adjustments To Additional Paid In Capital Acquisition Of Remaining Portion Of Affiliate AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate	50000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4377000
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-150000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63485000
CY2023	ibio	Stock Issued During Period Value Capital Raise StockIssuedDuringPeriodValueCapitalRaise	12327000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	636000
CY2023	ibio	Asset Acquisition Value AssetAcquisitionValue	650000
CY2023	ibio	Fractional Share Issued After Reverse Stock Split Value FractionalShareIssuedAfterReverseStockSplitValue	-39000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4391000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	33000
CY2023	ibio	Reclassficiation Adjustment Gain Loss On Available For Sale Debt Securities ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities	21000
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	159000
CY2023	us-gaap	Profit Loss ProfitLoss	-65010000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15381000
CY2023	us-gaap	Profit Loss ProfitLoss	-65010000
CY2022	us-gaap	Profit Loss ProfitLoss	-50304000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4391000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4377000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	401000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	224000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	599000
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	356000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	516000
CY2023	us-gaap	Depreciation Depreciation	674000
CY2022	us-gaap	Depreciation Depreciation	2275000
CY2023	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	773000
CY2023	ibio	Accrued Interest Receivable On Convertible Promissory Note Receivable AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable	75000
CY2022	ibio	Accrued Interest Receivable On Convertible Promissory Note Receivable AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable	75000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	67000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	312000
CY2023	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-98000
CY2023	ibio	Deferred Financing Costs Amortization Expense DeferredFinancingCostsAmortizationExpense	242000
CY2022	ibio	Deferred Financing Costs Amortization Expense DeferredFinancingCostsAmortizationExpense	107000
CY2023	ibio	Increase Decrease In Inventory Reserve IncreaseDecreaseInInventoryReserve	4915000
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17900000
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	565000
CY2023	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	5000
CY2022	ibio	Forgiveness Of Note Payable And Accrued Interest Sba Loan ForgivenessOfNotePayableAndAccruedInterestSbaLoan	607000
CY2022	ibio	Settlement Of Revenue Contract SettlementOfRevenueContract	84000
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	1760000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	886000
CY2023	ibio	Increase Decrease In Settlement Assets IncreaseDecreaseInSettlementAssets	-5100000
CY2022	ibio	Increase Decrease In Settlement Assets IncreaseDecreaseInSettlementAssets	-5100000
CY2023	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	1015000
CY2022	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	3873000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-885000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-307000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-74000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	74000
CY2023	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-21000
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-5000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-625000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1239000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	145000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1443000
CY2023	ibio	Increase Decrease In Accrued Liabilities Noncurrent IncreaseDecreaseInAccruedLiabilitiesNoncurrent	527000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-101000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-15000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-100000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30436000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37480000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5355000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4100000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13618000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	6739000
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	1760000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4300000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5738000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7330000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2600000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	692000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7009000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5127000
CY2023	ibio	Proceeds From Issuance Of Preferred And Common Stock ProceedsFromIssuanceOfPreferredAndCommonStock	11487000
CY2023	ibio	Payments For Fractional Shares After Reverse Stock Split PaymentsForFractionalSharesAfterReverseStockSplit	39000
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	50000
CY2023	ibio	Proceeds From Equipment Financing Loan ProceedsFromEquipmentFinancingLoan	500000
CY2023	ibio	Payment Of Equipment Financing Loan PaymentOfEquipmentFinancingLoan	99000
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	9318000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000
CY2023	ibio	Payments To Attain Term Note PaymentsToAttainTermNote	22000
CY2022	ibio	Payments To Attain Term Note PaymentsToAttainTermNote	322000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	208000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5830000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2301000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6125000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21093000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48732000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28672000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77404000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7579000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28672000
CY2023	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	1769000
CY2022	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	791000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	814000
CY2023	ibio	Increase Decrease In Finance Lease Obligations For New Leases IncreaseDecreaseInFinanceLeaseObligationsForNewLeases	814000
CY2023	ibio	Common Stock Issued In Rubryc Transaction Value CommonStockIssuedInRubrycTransactionValue	650000
CY2023	ibio	Cost To Raise Capital Paid Directly From Gross Proceeds CostToRaiseCapitalPaidDirectlyFromGrossProceeds	636000
CY2023	ibio	Non Cash Transaction Of Subscription Receivable For Capital Raise NonCashTransactionOfSubscriptionReceivableForCapitalRaise	204000
CY2023	ibio	Cost Accrued To Amend Term Note Payable CostAccruedToAmendTermNotePayable	125000
CY2022	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	1769000
CY2022	ibio	Termination Of Finance Lease Right Of Use Asset Including Issuance Of Warrant TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant	25386000
CY2022	us-gaap	Notes Issued1 NotesIssued1	22375000
CY2022	ibio	Non Cash Transaction Increase In Right Of Use Assets And Liabilities NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities	5570000
CY2022	ibio	Non Cash Settlement Of Revenue Contract NonCashSettlementOfRevenueContract	580000
CY2022	ibio	Warrants Issued For Finance Lease Payment WarrantsIssuedForFinanceLeasePayment	217000
CY2022	ibio	Lease Incentive For Construction In Progress LeaseIncentiveForConstructionInProgress	-82000
CY2022	ibio	Noncash Or Part Noncash Acquisition Non Controlling Interest Assumed NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed	18000
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	159000
CY2022	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	150000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	687000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1045000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1. </b><b style="font-weight:bold;">Nature of Business</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, iBio made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc"). This acquisition commenced our transition to an AI-enabled biotech company and led to the divestiture of our Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed us focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of iBio’s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with unprecedented precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. Another integral part of iBio’s technology stack is the machine learning (ML) based antibody-optimizing StableHu™ technology. When coupled with our mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio also developed the EngageTx™ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of our antibody products. By incorporating EngageTx into iBio’s own development initiatives, the Company’s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to our potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">iBio’s scientific team, composed of experienced AI/ML scientists and drug hunters located side-by-side in our San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows us to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company’s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Clinical Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">iBio is currently in the process of building and advancing its preclinical pipeline. The focus of this pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging iBio’s technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">on the learnings of competitors, iBio's programs are primarily adopting a fast follower strategy. This approach allows iBio to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20230630x10k030.jpg" style="display:inline-block;height:171.6pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Digital Infrastructure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">iBio is a firm believer in the transformative power of digital technologies, including robotics, automation, artificial intelligence (AI), machine learning (ML), and cloud computing. These technologies are integral to operationalizing our strategy, accelerating our learning curve, and executing at scale. As such, the Company has made substantial investments in these areas. iBio’s aspiration is to digitize our operations to the greatest extent possible, harnessing the potential of digital technology to maximize our impact on human health. As the Company continues to grow, we remain committed to further investing in our digital infrastructure to support our ambitious goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Strategic Alliances, Collaborations, and Joint Ventures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio has formed collaborations and strategic alliances to gain access to funding, capabilities, technical resources and intellectual property to further its development efforts, commercialize its technology and to generate revenues, including through the use of our patented epitope-steering AI-engine and our EngageTX platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"></span></p>
CY2022Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.60
CY2022Q4	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	69
CY2023Q2	ibio	Cash And Cash Equivalents Plus Debt Securities CashAndCashEquivalentsPlusDebtSecurities	7600000
CY2022Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.60
CY2022Q4	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	69
CY2022Q4	us-gaap	Area Of Land AreaOfLand	130000
CY2022Q4	ibio	Employee Reduction Expenses EmployeeReductionExpenses	1900000
CY2022Q4	ibio	Severance Transitional Period Days SeveranceTransitionalPeriodDays	60
CY2023	ibio	Employee Reduction Expenses EmployeeReductionExpenses	35700000
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17900000
CY2023	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	4900000
CY2023Q2	ibio	Disposal Group Including Discontinued Operation Personnel Costs Including Severance DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance	7500000
CY2023	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	391000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	499000
CY2023	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	52000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	216000
CY2023	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	339000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	283000
CY2023	ibio	Discontinued Operations Research And Development Expenses DiscontinuedOperationsResearchAndDevelopmentExpenses	6344000
CY2022	ibio	Discontinued Operations Research And Development Expenses DiscontinuedOperationsResearchAndDevelopmentExpenses	7902000
CY2023	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	6751000
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	12373000
CY2023	ibio	Tangible Asset Impairment Charges Discontinued Operations TangibleAssetImpairmentChargesDiscontinuedOperations	17900000
CY2023	ibio	Gain On Sale Of Fixed Assets GainOnSaleOfFixedAssets	-773000
CY2023	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	4915000
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	35137000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	20275000
CY2023	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	900000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	602000
CY2022	ibio	Disposal Group Interest Expense Related Party DisposalGroupInterestExpenseRelatedParty	810000
CY2022	ibio	Disposal Group Gain On Debt Forgiveness DisposalGroupGainOnDebtForgiveness	607000
CY2023	ibio	Discontinued Operations Miscellaneous Expenses Income DiscontinuedOperationsMiscellaneousExpensesIncome	1000
CY2022	ibio	Discontinued Operations Miscellaneous Expenses Income DiscontinuedOperationsMiscellaneousExpensesIncome	-6000
CY2023	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	901000
CY2022	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	799000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-35699000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-20791000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	3900000
CY2023Q2	ibio	Disposal Group Operating Lease Right Of Use Assets DisposalGroupOperatingLeaseRightOfUseAssets	1941000
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Current DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent	16124000
CY2023Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	18065000
CY2022Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	3900000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent	35289000
CY2022Q2	ibio	Disposal Group Non Current Assets Finance Lease Right Of Use Assets DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets	74000
CY2022Q2	ibio	Disposal Group Operating Lease Right Of Use Assets Noncurrent DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent	1951000
CY2022Q2	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	37314000
CY2022Q2	ibio	Disposal Group Current Liabilities Finance Lease Obligations DisposalGroupCurrentLiabilitiesFinanceLeaseObligations	46000
CY2023Q2	ibio	Disposal Group Current Liabilities Operating Lease Obligations DisposalGroupCurrentLiabilitiesOperatingLeaseObligations	1941000
CY2022Q2	ibio	Disposal Group Current Liabilities Operating Lease Obligations DisposalGroupCurrentLiabilitiesOperatingLeaseObligations	10000
CY2023Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1941000
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	56000
CY2022Q2	ibio	Disposal Group Noncurrent Liabilities Finance Lease Obligations DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations	30000
CY2022Q2	ibio	Disposal Group Noncurrent Operating Lease Obligations DisposalGroupNoncurrentOperatingLeaseObligations	1941000
CY2022Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	1971000
CY2023	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	273000
CY2022	us-gaap	Depreciation And Amortization Discontinued Operations DepreciationAndAmortizationDiscontinuedOperations	2275000
CY2023	ibio	Disposal Group Amortization Of Finance Lease Right Of Use Assets DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets	20000
CY2022	ibio	Disposal Group Amortization Of Finance Lease Right Of Use Assets DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets	599000
CY2023	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	1542000
CY2022	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	5809000
CY2023	ibio	Tangible Asset Impairment Charges Discontinued Operations TangibleAssetImpairmentChargesDiscontinuedOperations	17900000
CY2023	ibio	Disposal Group Including Discontinued Operation Inventory Write Down DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown	4915000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2600000
CY2022	ibio	Increase In Rou Operating Assets And Liabilities For New Leases IncreaseInRouOperatingAssetsAndLiabilitiesForNewLeases	1952000
CY2023	ibio	Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod	1542000
CY2022	ibio	Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod	791000
CY2022	ibio	Unpaid Fixed Assets Attributable To Discontinued Operations UnpaidFixedAssetsAttributableToDiscontinuedOperations	1542000
CY2022	ibio	Termination Of Finance Rou Assets Including Issuance Of Warrant TerminationOfFinanceRouAssetsIncludingIssuanceOfWarrant	25386000
CY2022	ibio	Proceeds From Notes Payable From Discontinued Operations ProceedsFromNotesPayableFromDiscontinuedOperations	22375000
CY2022	ibio	Issuance Of Warrant For Final Lease Obligation Payment IssuanceOfWarrantForFinalLeaseObligationPayment	217000
CY2023	us-gaap	Interest Paid Discontinued Operations InterestPaidDiscontinuedOperations	603000
CY2022	us-gaap	Interest Paid Discontinued Operations InterestPaidDiscontinuedOperations	1045000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p>
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023	us-gaap	Revenues Revenues	0
CY2022Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2023Q2	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	178000
CY2023Q2	ibio	Percentage Of Collateral Required PercentageOfCollateralRequired	0.05
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	3278000
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	5996000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4301000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22676000
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	7579000
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	28672000
CY2022Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3896000
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	4000
CY2022Q2	us-gaap	Inventory Net InventoryNet	3900000
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	5003000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4851000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At June 30, 2023 and 2022, amounts in excess of insured limits were approximately $6,900,000 and $18,200,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated $391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30, 2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers.</p>
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6900000
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	18200000
CY2023	us-gaap	Revenues Revenues	0
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5388000
CY2021Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	7500000
CY2021Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	7500000
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent	1100000
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11029000
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	401000
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	8054000
CY2022Q2	ibio	Available For Sale Securities Debt Maturities With In Two Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithInTwoYearAmortizedCost	2791000
CY2022Q2	us-gaap	Debt Securities Current DebtSecuritiesCurrent	10845000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	67000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	312000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	6739000
CY2023	ibio	Cost Of Debt Securities CostOfDebtSecurities	6837000
CY2023	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-98000
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	204000
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	610000
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	204000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	0
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	563000
CY2023	ibio	Operating Cash Flows From Operating Lease Obligation OperatingCashFlowsFromOperatingLeaseObligation	307000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2722000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	11383
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3603000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2722000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3068000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1967000
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4619000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1373000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	400000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4219000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	400000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0
CY2023Q2	ibio	Fixed Assets Held For Sale FixedAssetsHeldForSale	16124000
CY2022Q2	ibio	Fixed Assets Held For Sale FixedAssetsHeldForSale	35289000
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	17900000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5946000
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	400000
CY2023	ibio	Impairment Of Intangible Assets Gross Of Reversals ImpairmentOfIntangibleAssetsGrossOfReversals	5946000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	400000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5270000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126000
CY2023	ibio	Reversal Of Intangible Asset Impairment ReversalOfIntangibleAssetImpairment	5381000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15000
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	676000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126000
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	400000
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	565000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	385000
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4175000
CY2023	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	828000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	20000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	20000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	20000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	20000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	285000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	385000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3352000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3066000
CY2023Q2	ibio	Accrued Real Estate Taxes AccruedRealEstateTaxes	268000
CY2022Q2	ibio	Accrued Real Estate Taxes AccruedRealEstateTaxes	284000
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	183000
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	59000
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	31000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	126000
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	200000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	229000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4034000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3764000
CY2023Q1	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	5100000
CY2022Q4	ibio	Equipment Financing Amount Borrowed EquipmentFinancingAmountBorrowed	500000
CY2022Q4	ibio	Lessee Equipment Lease Term Of Contract LesseeEquipmentLeaseTermOfContract	P36M
CY2022Q4	ibio	Equipment Financing Lease Imputed Interest Rate EquipmentFinancingLeaseImputedInterestRate	0.1062
CY2022Q4	ibio	Equipment Leasing Monthly Installment Payable EquipmentLeasingMonthlyInstallmentPayable	16230
CY2023Q2	ibio	Equipment Financing Balance EquipmentFinancingBalance	401000
CY2023	ibio	Equipment Financing Interest Incurred EquipmentFinancingInterestIncurred	31000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	389000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3125000
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-29311000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-29512000
CY2023Q2	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	195000
CY2023Q2	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	194000
CY2023Q2	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	65000
CY2023Q2	us-gaap	Contractual Obligation ContractualObligation	454000
CY2021Q2	ibio	Lessor Finance Lease Monthly Rent LessorFinanceLeaseMonthlyRent	3819
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	224000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	49000
CY2023	us-gaap	Lease Cost LeaseCost	273000
CY2023	ibio	Financing Cash Flows From Finance Lease Obligation FinancingCashFlowsFromFinanceLeaseObligation	208000
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	610000
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	272000
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	351000
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M1D
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0950
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	319000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	319000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	53000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	691000
CY2021Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	11383
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P88M
CY2021Q3	ibio	Lessee Operating Lease Monthly Rent LesseeOperatingLeaseMonthlyRent	51223
CY2021Q3	ibio	Lessee Operating Lease Annual Percentage Increase In Base Rent LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent	0.03
CY2021Q3	us-gaap	Tenant Improvements TenantImprovements	81860
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	563000
CY2023	ibio	Total Operating Lease Costs TotalOperatingLeaseCosts	563000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	389000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year One LesseeOperatingLeaseImputedInterestToBePaidYearOne	242000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year One LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne	631000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	436000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Two LesseeOperatingLeaseImputedInterestToBePaidYearTwo	212000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Two LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo	648000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	490000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Three LesseeOperatingLeaseImputedInterestToBePaidYearThree	179000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Three LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree	669000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	546000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Four LesseeOperatingLeaseImputedInterestToBePaidYearFour	142000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Four LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour	688000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	610000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Year Five LesseeOperatingLeaseImputedInterestToBePaidYearFive	100000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Five LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive	710000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1043000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid After Year Five LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive	61000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid After Year Five LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive	1104000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3514000
CY2023Q2	ibio	Lessee Operating Lease Imputed Interest To Be Paid Total LesseeOperatingLeaseImputedInterestToBePaidTotal	936000
CY2023Q2	ibio	Lessee Operating Lease Liability Principal And Imputed Interest LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest	4450000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	389000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3125000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3380
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	88000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29311000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29600000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-35699000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-20791000
CY2023	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-65010000
CY2022	ibio	Unconsolidated Gain Loss Attributable To Stockholders UnconsolidatedGainLossAttributableToStockholders	-50391000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12245000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8721000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.39
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.39
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.92
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.39
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.31
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.78
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6411000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	694000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2863000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3958000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	341686
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1995000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	313568
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.50
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3380
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	22.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	30068
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	35.00
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	621806
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	620810
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	30.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	197404
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	29.25
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	621806
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	307863
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.06
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	637191
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	23.96
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	292478
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.18
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	292431
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.18
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	96050
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	29.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	292478
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	28.31
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	96050
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4828000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3334000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	77000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	19000
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2193000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.30
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	23.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0321
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0361
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0080
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0252
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1552
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1693
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.1916
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2034
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q2	us-gaap	Share Price SharePrice	0.61
CY2022Q2	us-gaap	Share Price SharePrice	6.50
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12153000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-9051000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-637000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-12790000
CY2022	ibio	Current And Deferred Federal And State Taxes CurrentAndDeferredFederalAndStateTaxes	-9051000
CY2023	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	12790000
CY2022	ibio	Income Tax Expense Benefit Valuation Allowance IncomeTaxExpenseBenefitValuationAllowance	9051000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2023	ibio	Effective Income Tax Rate Reconciliation Expiration Forfeiture Of Stock Options EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions	-0.02
CY2022	ibio	Effective Income Tax Rate Reconciliation Expiration Forfeiture Of Stock Options EffectiveIncomeTaxRateReconciliationExpirationForfeitureOfStockOptions	0
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42951000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35829000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	883000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1248000
CY2023Q2	ibio	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	2775000
CY2022Q2	ibio	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	0
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1764000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1764000
CY2023Q2	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	395000
CY2022Q2	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	370000
CY2023Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	121000
CY2022Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2520000
CY2023Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	42000
CY2022Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	71000
CY2023Q2	ibio	Deferred Tax Asset Operating And Finance Lease Liabilities DeferredTaxAssetOperatingAndFinanceLeaseLiabilities	1363000
CY2022Q2	ibio	Deferred Tax Asset Operating And Finance Lease Liabilities DeferredTaxAssetOperatingAndFinanceLeaseLiabilities	0
CY2023Q2	ibio	Deferred Tax Liabilities Operating And Finance Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets	1184000
CY2022Q2	ibio	Deferred Tax Liabilities Operating And Finance Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingAndFinanceLeaseRightOfUseAssets	0
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	529000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	145000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49555000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36765000
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2008Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	5500000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	202100000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	63900000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	138200000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	35200000
CY2023	ibio	Effective Income Tax Rate Reconciliation Change Related To Ibio Cdmo EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo	0
CY2022	ibio	Effective Income Tax Rate Reconciliation Change Related To Ibio Cdmo EffectiveIncomeTaxRateReconciliationChangeRelatedToIbioCdmo	-0.03
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.18
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	263000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	169000

Files In Submission

Name	View Source	Status
ibio-20230630_cal.xml	Edgar Link	unprocessable
0001420720-23-000045-index-headers.html	Edgar Link	pending
0001420720-23-000045-index.html	Edgar Link	pending
0001420720-23-000045.txt	Edgar Link	pending
0001420720-23-000045-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibio-20230630.xsd	Edgar Link	pending
ibio-20230630x10k.htm	Edgar Link	pending
ibio-20230630x10k001.jpg	Edgar Link	pending
ibio-20230630x10k002.jpg	Edgar Link	pending
ibio-20230630x10k003.jpg	Edgar Link	pending
ibio-20230630x10k004.jpg	Edgar Link	pending
ibio-20230630x10k005.jpg	Edgar Link	pending
ibio-20230630x10k006.jpg	Edgar Link	pending
ibio-20230630x10k007.jpg	Edgar Link	pending
ibio-20230630x10k008.jpg	Edgar Link	pending
ibio-20230630x10k009.jpg	Edgar Link	pending
ibio-20230630x10k010.jpg	Edgar Link	pending
ibio-20230630x10k011.jpg	Edgar Link	pending
ibio-20230630x10k012.jpg	Edgar Link	pending
ibio-20230630x10k013.jpg	Edgar Link	pending
ibio-20230630x10k014.jpg	Edgar Link	pending
ibio-20230630x10k015.jpg	Edgar Link	pending
ibio-20230630x10k016.jpg	Edgar Link	pending
ibio-20230630x10k017.jpg	Edgar Link	pending
ibio-20230630x10k018.jpg	Edgar Link	pending
ibio-20230630x10k019.jpg	Edgar Link	pending
ibio-20230630x10k020.jpg	Edgar Link	pending
ibio-20230630x10k021.jpg	Edgar Link	pending
ibio-20230630x10k022.jpg	Edgar Link	pending
ibio-20230630x10k023.jpg	Edgar Link	pending
ibio-20230630x10k024.jpg	Edgar Link	pending
ibio-20230630x10k025.jpg	Edgar Link	pending
ibio-20230630x10k026.jpg	Edgar Link	pending
ibio-20230630x10k027.jpg	Edgar Link	pending
ibio-20230630x10k028.jpg	Edgar Link	pending
ibio-20230630x10k030.jpg	Edgar Link	pending
ibio-20230630xex21d1.htm	Edgar Link	pending
ibio-20230630xex23d1.htm	Edgar Link	pending
ibio-20230630xex31d1.htm	Edgar Link	pending
ibio-20230630xex31d2.htm	Edgar Link	pending
ibio-20230630xex32d1.htm	Edgar Link	pending
ibio-20230630xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
ibio-20230630_def.xml	Edgar Link	unprocessable
ibio-20230630_lab.xml	Edgar Link	unprocessable
ibio-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ibio-20230630x10k_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2023 Q3 Form 10-K Financial Statement

#000142072023000045 Filed on September 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2023 Q3 Form 10-K Financial Statement

#000142072023000045 Filed on September 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio